Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer
Authors:
Open Access
- 4 October 2012
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 132 (9) , 2209-2216
Abstract
The prognostic impact of CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) on the treatment outcome of colon cancer patients receiving adjuvant 5‐fluorouracil/leucovorin/oxaliplatin (FOLFOX) is unclear. We investigated CIMP and MSI status in colorectal cancer patients treated with adjuvant FOLFOX. Stages II and III sporadic colorectal cancer patients who underwent curative resection followed by adjuvant FOLFOX were included. Eight CpG island loci (CACNA1G, CRABP1, IGF2, MLH1, NEUROG1, CDKN2A (p16), RUNX3 and SOCS1) and five microsatellite markers were examined. Disease‐free survival (DFS) was analyzed according to CIMP and MSI status. A total of 322 patients were included: male/female 192/130, median age 61 years (range 30–78), proximal/distal location 118/204 and Stages II/III 43/279. CIMP status was high in 25 patients (7.8%) and 21 patients (6.5%) had MSI‐high tumor. CIMP/MSI status was not significantly associated with DFS: 3‐year DFS 100% in CIMP(−)/MSI(+), 84% in CIMP(−)/MSI(−), 82% in CIMP(+)/MSI(−) and 75% in CIMP(+)/MSI(+) (p = 0.33). Results of exploratory analysis showed that concurrent methylation at NEUROG1 and CDKN2A (p16) was associated with shorter DFS: 3‐year DFS 69% in NEUROG1(+)/CDKN2A (p16)(+) versus 87% in NEUROG1(−)/CDKN2A (p16)(−) (p = 0.006). In conclusion, concurrent methylation of NEUROG1 and CDKN2A (p16) is associated with recurrence following adjuvant FOLFOX in Stages II/III colorectal cancer.Keywords
This publication has 40 references indexed in Scilit:
- Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX ChemotherapyClinical Cancer Research, 2011
- 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal CancerGastroenterology, 2011
- DNA methylation predicts recurrence from resected stage III proximal colon cancerCancer, 2010
- Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature reviewInternational Journal of Cancer, 2010
- Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapyCancer Chemotherapy and Pharmacology, 2009
- Molecular Basis of Colorectal CancerNew England Journal of Medicine, 2009
- Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatinAnnals of Oncology, 2009
- Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 CasesCancer Research, 2008
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancerGut, 2008
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006